CanBas Co., Ltd.
TTSE:4575723.00
JPY
-33.00
(-4.37%)
ISIN
JP3244570002
Return %
Stock
S&P 500
1Y
-30.35
14.20
3Y
-25.31
81.12
5Y
221.33
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Takumi Kawabe
- Full Time Employees
- 18
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 2-2-1, Otemachi Numazu SZ Japan 410-0801
- IPO Date
- Sep 18, 2009
- Website
- canbas.co.jp
- Similar Companies
- Business
- CanBas Co., Ltd., founded in 2000 and headquartered in Numazu, Japan, is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel oncology drugs targeting the cell cycle. The company’s main products include CBP501, a calmodulin-modulating peptide designed to enhance the efficacy of cisplatin in treating various cancers; and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. These therapeutics are primarily developed for cancer patients, focusing on advanced malignant solid neoplasms and are part of a pipeline that includes other investigational compounds targeting neoplasms. CanBas operates primarily in Japan but engages in global research collaborations. Recent strategic developments include a collaboration alliance with Stemline Therapeutics, Inc., enhancing its research and development capabilities. The company is progressing with clinical trials, including Phase 1b completion and preparing for Phase 2 trials for CBP501 targeting third-line pancreatic cancer. Other ongoing clinical trials involve combinations of CBP501 with cisplatin and nivolumab in advanced refractory tumors, reflecting an expansion of its therapeutic offerings in oncology. CanBas maintains research partnerships such as a joint screening agreement with Fuji Pharma Valley Project, supporting its drug discovery efforts. The company has strengthened its scientific advisory board with eminent experts from prominent cancer research institutions. CanBas’s comprehensive product and service offerings consist of developing peptide and small molecule drugs to disrupt cancer cell cycles and checkpoints, utilizing proprietary screening systems. Its pipeline emphasizes targeted cancer therapies with lower toxicity to normal cells, leveraging advanced biochemical and molecular biology technologies. The company remains focused on innovation in oncology drug discovery and is positioned as a specialized entity within the biotechnology and pharmaceutical sectors in Japan and internationally. The company’s financial and operational metrics reflect its status as a clinical-stage developer, investing heavily in research and clinical trials, with a market capitalization in the range of billions of yen as of 2025. CanBas’s latest business expansion activities center on advancing clinical stages of its pipeline products and augmenting global collaborative research alliances to accelerate therapeutic development and commercialization potential.